Opthea Limited Sponsored ADR (OPT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...

Opthea Limited ( ($AU:OPT) ) has shared an update. Opthea Limited announced plans to host Investor Days in New York and Australia to discuss ...

An announcement from Opthea Limited ( ($AU:OPT) ) is now available. Opthea Limited announced the publication of its Phase 1b ...

Business update to include masked Phase 3 patient demographics and baseline characteristics Presentation on Wednesday, January 15, 2025, 5:15 PM PT in San Francisco, California MELBOURNE ...

Opthea Limited (AU:OPT) has released an update. Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks Make smarter investments with weekly ...

MELBOURNE, Australia and PRINCETON, N.J., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage ...

MELBOURNE, Australia and PRINCETON, N.J. - Opthea Limited (ASX/NASDAQ: OPT), a biopharmaceutical company focused on developing treatments for retinal diseases, has published the results of its ...

Opthea Limited, a clinical-stage biopharmaceutical company focused on developing therapies for retinal diseases, announced that its CEO, Frederic Guerard, will present at the 43rd Annual J.P ...

Pengana’s James McDonald is tipping into Aussie names Telix and Opthea, potash producer K+S, and the valuation case for Ardent at 70¢. The Carlyle Group and its newly acquired life sciences arm ...

Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including ...

MELBOURNE, Australia and PRINCETON, N.J. - Opthea Limited (ASX/NASDAQ: OPT), a biopharmaceutical company focused on developing treatments for retinal diseases, has published the results of its Phase ...

Opthea Limited (ASX/NASDAQ: OPT“Opthea”, the“Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases ...